I’m thinking of that period of nearly a year when the SEC was doing a deep dive into everything Generex, and how investors, impatient for both news and share price progress, assumed negligence on the part of management. And how it turned out that circumstances were just beyond the company’s control. A perfectly good explanation when all was revealed.
I think we’ll find that while the details will be different, that ‘circumstances out of the company’s control’ are responsible for current delays in re the IND, the IPO and the re-launch of Excellagen.
(2)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links